SecSonar.com

AnaptysBio, Inc. (ANAB)

AnaptysBio, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

AnaptysBio, Inc. (ANAB) is a Biotechnology company based in US with a market capitalization of $2.4B. Revenue grew 157.0% year-over-year and the company generated $19.6M in free cash flow. This page tracks ANAB's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 136 employees · IPO Jan 26, 2017

Valuation

Valuation & price

$63.15 · as of May 17, 2026 · -9.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

64.13

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$69.78$41.36$12.93Jul 25Dec 25Jul 26Jul 7, 25$15.63Jul 9, 25$17.16Jul 11, 25$17.47Jul 15, 25$17.75Jul 17, 25$17.79Jul 21, 25$17.45Jul 23, 25$18.00Jul 25, 25$17.96Jul 29, 25$17.48Jul 31, 25$16.37Aug 4, 25$16.15Aug 6, 25$15.03Aug 11, 25$13.33Aug 13, 25$13.81Aug 15, 25$13.43Aug 19, 25$13.19Aug 21, 25$13.57Aug 25, 25$13.40Aug 27, 25$13.60Aug 29, 25$13.55Sep 3, 25$15.02Sep 5, 25$14.60Sep 9, 25$14.75Sep 11, 25$15.47Sep 16, 25$12.93Sep 18, 25$14.05Sep 22, 25$14.27Sep 24, 25$14.76Sep 26, 25$15.72Sep 30, 25$20.41Oct 2, 25$20.89Oct 6, 25$20.17Oct 8, 25$21.22Oct 10, 25$20.91Oct 14, 25$21.23Oct 16, 25$22.93Oct 21, 25$22.74Oct 23, 25$22.67Oct 27, 25$24.12Oct 29, 25$24.08Oct 31, 25$24.39Nov 4, 25$23.16Nov 6, 25$25.47Nov 10, 25$22.65Nov 12, 25$22.06Nov 14, 25$22.55Nov 18, 25$24.67Nov 20, 25$25.11Nov 25, 25$27.67Nov 28, 25$27.77Dec 2, 25$27.27Dec 4, 25$28.87Dec 8, 25$29.67Dec 10, 25$29.97Dec 12, 25$29.96Dec 16, 25$30.02Dec 18, 25$31.69Dec 22, 25$33.55Dec 24, 25$33.34Dec 29, 25$33.94Jan 2, 26$29.97Jan 6, 26$29.27Jan 8, 26$29.20Jan 12, 26$32.69Jan 14, 26$33.51Jan 16, 26$30.45Jan 21, 26$31.12Jan 23, 26$31.69Jan 27, 26$33.15Jan 29, 26$31.90Feb 2, 26$33.69Feb 4, 26$32.25Feb 9, 26$33.30Feb 11, 26$36.83Feb 13, 26$35.39Feb 18, 26$36.55Feb 20, 26$36.13Feb 24, 26$36.94Feb 26, 26$37.41Mar 2, 26$36.61Mar 4, 26$40.37Mar 6, 26$36.94Mar 10, 26$41.34Mar 12, 26$42.53Mar 17, 26$44.86Mar 19, 26$43.15Mar 23, 26$41.81Mar 25, 26$43.59Mar 27, 26$38.26Mar 31, 26$36.97Apr 2, 26$38.45Apr 7, 26$41.41Apr 9, 26$45.69Apr 13, 26$45.81Apr 15, 26$45.25Apr 17, 26$45.00Apr 22, 26$53.55Apr 24, 26$58.88Apr 28, 26$66.11Apr 30, 26$65.73May 4, 26$69.78May 6, 26$67.36May 8, 26$69.33May 12, 26$65.58May 14, 26$62.19May 18, 26$58.74May 20, 26$60.08May 22, 26$59.71May 28, 26$57.02Jun 1, 26$53.14Jun 3, 26$51.24Jun 5, 26$50.37Jun 9, 26$51.63Jun 11, 26$54.24Jun 15, 26$59.51Jun 17, 26$56.77Jun 22, 26$59.99Jun 24, 26$58.48Jun 26, 26$63.15Jul 2, 26$63.42
$12.9352-week range$69.78
Loading valuation history…

Fundamentals

Key fundamentals

$2.4B

Market cap

157.0%

Revenue growth (YoY)

99.0%

Gross margin

$19.6M

Free cash flow (USD)

-$297.5M

Net debt

Net cash position

-2.1%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$16.7MFY 2017$10.0MFY 2018$5.0MFY 2019$8.0MFY 2020$75.0MFY 2021$63.2MFY 2022$10.3MFY 2023$17.2MFY 2024$91.3MFY 2025$234.6M
$16.7M$234.6M

Free cash flow by year

2016 → 2025

FY 2016$-9.1MFY 2017$-19.7MFY 2018$-49.6MFY 2019$-70.3MFY 2020$-14.7MFY 2021$-47.3MFY 2022$-74.0MFY 2023$-121.6MFY 2024$-135.7MFY 2025$19.6M
-$9.1M$19.6M

Gross margin by year

2021 → 2025

FY 2021-55.9%FY 2022-763.2%FY 2023-671.0%FY 2024-79.5%FY 202599.0%
-55.9%99.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventSublease AgreementJun 22, 2026Filing
  • 8-K eventDividend InformationMay 29, 2026Filing
  • 8-K eventFiscal Year ChangeMay 21, 2026Filing
  • 8-K eventFinancial Results and UpdatesMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 12, 2026Filing
  • 8-K eventCFO AppointmentMay 11, 2026Filing
  • Annual report10-K FiledApr 28, 2026Filing
  • 8-K eventSpin-Off CompletedApr 24, 2026Filing
  • 8-K eventSeparation and Distribution AgreementApr 20, 2026Filing
  • Insider sellInsider Sell $1.2MSchmid John P. · Director · $1.2MApr 1, 2026Filing

Questions

Frequently asked questions

What is AnaptysBio, Inc.'s market cap?

AnaptysBio, Inc. (ANAB) has a market capitalization of $2.4B.

What is ANAB's P/E ratio?

A meaningful P/E ratio is not available for ANAB — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ANAB's price-to-book (P/B) ratio?

ANAB trades at 64.13 times book value per share.

Are insiders buying ANAB stock?

SEC Form 4 filings show no open-market insider buys at AnaptysBio, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

RARE

Ultragenyx Pharmaceutical Inc.

$2.4B

TNGX

Tango Therapeutics, Inc.

$2.4B

ADPT

Adaptive Biotechnologies Corporation

$2.5B

RCUS

Arcus Biosciences, Inc.

$2.5B

TARS

Tarsus Pharmaceuticals, Inc.

$2.6B

IDYA

IDEAYA Biosciences, Inc.

$2.6B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.